- Home
- VBF vs CHRS Comparison
VBF vs CHRS Comparison
Compare VBF & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VBF
- CHRS
- Stock Information
- Founded
- VBF 1970
- CHRS 2010
- Country
- VBF United States
- CHRS United States
- Employees
- VBF N/A
- CHRS 235
- Industry
- VBF Trusts Except Educational Religious and Charitable
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VBF Finance
- CHRS Health Care
- Exchange
- VBF Nasdaq
- CHRS Nasdaq
- Market Cap
- VBF 177.3M
- CHRS 134.4M
- IPO Year
- VBF N/A
- CHRS 2014
- Fundamental
- Price
- VBF $15.82
- CHRS $1.22
- Analyst Decision
- VBF
- CHRS Strong Buy
- Analyst Count
- VBF 0
- CHRS 4
- Target Price
- VBF N/A
- CHRS $5.38
- AVG Volume (30 Days)
- VBF 45.5K
- CHRS 2.4M
- Earning Date
- VBF 01-01-0001
- CHRS 03-12-2025
- Dividend Yield
- VBF 5.18%
- CHRS N/A
- EPS Growth
- VBF N/A
- CHRS N/A
- EPS
- VBF N/A
- CHRS N/A
- Revenue
- VBF N/A
- CHRS $304,340,000.00
- Revenue This Year
- VBF N/A
- CHRS $2.47
- Revenue Next Year
- VBF N/A
- CHRS N/A
- P/E Ratio
- VBF N/A
- CHRS N/A
- Revenue Growth
- VBF N/A
- CHRS 44.19
- 52 Week Low
- VBF $13.68
- CHRS $0.66
- 52 Week High
- VBF $16.27
- CHRS $2.87
- Technical
- Relative Strength Index (RSI)
- VBF 56.46
- CHRS 44.03
- Support Level
- VBF $15.67
- CHRS $1.03
- Resistance Level
- VBF $16.09
- CHRS $1.23
- Average True Range (ATR)
- VBF 0.19
- CHRS 0.13
- MACD
- VBF 0.04
- CHRS -0.02
- Stochastic Oscillator
- VBF 58.46
- CHRS 38.89
About VBF Invesco Bond Fund
Invesco Bond Fund is an independent investment management firm. Its investment objective is to seek interest income while conserving capital.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.